Clinical Trials Logo

IDH2 Gene Mutation clinical trials

View clinical trials related to IDH2 Gene Mutation.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04522895 Active, not recruiting - Clinical trials for Myelodysplastic Syndromes

IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT

Start date: August 27, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective, open label, single arm, multi-centre phase II trial aiming to evaluate the safety and efficacy of Enasidenib (investigational product) as prophylactic consolidation in patients with IDH2-mutated MDS, CMML and AML in remission after allo-SCT.

NCT ID: NCT03180502 Active, not recruiting - Glioma Clinical Trials

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

Start date: August 2, 2017
Phase: Phase 2
Study type: Interventional

This randomized phase II clinical trial studies the side effects and how well proton beam or intensity-modulated radiation therapy works in preserving brain function in patients with IDH mutant grade II or III glioma. Proton beam radiation therapy uses tiny charged particles to deliver radiation directly to the tumor and may cause less damage to normal tissue. Intensity-modulated or photon beam radiation therapy uses high-energy x-ray beams shaped to treat the tumor and may also cause less damage to normal tissue. Patients will be more likely to be randomized to proton beam radiation therapy. It is not yet known if proton beam radiation therapy is more effective than photon-based beam intensity-modulated radiation therapy in treating patients with glioma.